UK Is First To Sign Up Pfizer For COVID-19 Vaccine, AstraZeneca For Antibodies
Valneva Also Agrees 60 Million Dose Deal
The UK's vaccine strategy spread its bets over three candidates so far, as the country also looks to prove its world-class status in life sciences research and manufacturing.
You may also be interested in...
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.